Before HER2-low breast cancer was clinically recognized, patients within this subgroup were typically managed according to HER2-positive or HER2-negative protocols, which often resulted in suboptimal therapeutic benefit and unnecessary toxicities due to inadequate target engagement or overtreatment [20]. This evidence concerns the gene ERBB2 and breast carcinoma.